inhibitor

(redirected from dipeptidyl peptidase-4 inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
See: deterrent
References in periodicals archive ?
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
LOS ANGELES--The distinct possibility that using dipeptidyl peptidase-4 inhibitors to treat hyperglycemia in type 2 diabetic patients may substantially reduce the risk of major cardiovascular events has been raised in a comprehensive new meta-analysis of randomized controlled trials.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitaglipim added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Lack of dermal toxicity with the highly selective dipeptidyl peptidase-4 inhibitor alogliptin in monkeys.
There are seven pharmacologic subclasses of oral antidiabetic agents: alpha-glucosidase inhibitors, biguanides, dipeptidyl peptidase-4 inhibitors, meglitinides, sulfonylureas, sodium-glucose cotransporter-2 inhibitors, and thiazolidinediones.
This includes new medication classes as add-on therapy to metformin such as the dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists that act on the incretin system, and the sodium glucose cotransporter-2 inhibitors that act on the kidney.

Full browser ?